Last edition
News about "Sandeep Jain"
Akums Receives First UK MHRA Approval for Rivaroxaban
Rivaroxaban is an oral anticoagulant prescribed for the prevention and treatment of thromboembolic disorders, including Non-Valvular Atrial Fibrillation (NVAF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE) and clinically relevant cardiovascular risk reduction.
Sandeep Jain | 10/02/2026 | By News Bureau
Akums Secures EU GMP Approval for Two Haridwar Facilities
The approvals follow successful EU-GMP audits of Akums’ two Haridwar manufacturing facilities, with the drug regulator renewing certification for plant I and granting fresh approval to plant II after assessing operations, quality systems, documentation and compliance with EU GMP standards.
Sandeep Jain | 23/01/2026 | By News Bureau
Akums Launches Enhanced Gabapentin ER Formulation for PHN
Akums Drugs and Pharmaceutical has introduced an enhanced Gabapentin Extended-Release (ER) formulation powered by its RetenEx technology for the management of postherpetic neuralgia (PHN), a chronic neuropathic pain condition that affects around 10-20 percent of patients following a shingles outbreak.
Sandeep Jain | 15/12/2025 | By News Bureau | 100
Akums's Hormonal Plant Gets EAEU GMP Nod, Expands into Eurasia
Akums’s Hormonal Plant receives EAEU GMP certification for oral hormonal tablets, enabling entry into Eurasian markets with therapies for women’s health, HRT and endocrine care.
Sandeep Jain | 09/09/2025 | By Dineshwori | 256
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy